p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1154-1162

  Schmieder, Michael ^a   Wolf, Sebastian ^a   Danner, Bettina ^a   Stoehr, Susanne ^a   Juchems, Markus S ^a   Wuerl, Peter ^a   Henne Bruns, Doris ^a   Knippschild, Uwe ^a   Hasel, Cornelia ^a   Kramer, Klaus ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN P16; STEM CELL FACTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 54249150409     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08646     Document Type: Article

References (52)

1. Kindblom LG, Meis-Kindblom JM, and Bumming P (2002). Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST) - a population-based study of 600 cases. Ann Oncol 13, 157.
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33, 459-465.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
5. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, and Swallow CJ (2001). Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8, 50-59.
6. Eisenberg BL and Judson I (2004). Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11, 465-475.
7. Miettinen M, El-Rifai W, HL Sobin L, and Lasota J (2002). Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33, 478-483.
8. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, and Nielsen OS (2002). Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 (Suppl 5), S83-S87.
9. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, and Peinado MA (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19, 299-304.
10. INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 19, 134-140.
11. Hilton DA, Penney M, Evans B, Sanders H, and Love S (2002). Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 26, 472-478.
12. INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 201, 487-495.
13. Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O'Sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, et al. (2003). Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 9, 2177-2184.
14. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, et al. (2005). Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11, 638-645.
15. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J, Langer C, Ramadori G, Sultmann H, and Fuzesi L (2005). Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11, 6589-6597.
16. INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 13, 1633-1644.
17. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, et al. (2005). 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 104, 159-169.
18. Ricci R, Arena V, Castri F, Martini M, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, and Larocca LM (2004). Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 122, 35-43.
19. INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol 17, 1364-1371.
20. Sabah M, Cummins R, Leader M, and Kay E (2006). Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 37, 648-655.
21. INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21, 1688-1697.
22. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Loberg EM, Isaksen V, Eide TJ, and Nielsen TO (2008). Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 21, 46-53.
23. Hohenberger P, Reichardt P, Gebauer B, and Wardelmann E (2004). Gastrointestinal stromal tumors (GIST) - current concepts of surgical management. Dtsch Med Wochenschr 129, 1817-1820.
24. Iesalnieks I, Rummele P, Dietmaier W, Jantsch T, Zulke C, Schlitt HJ, Hofstadter F, and Anthuber M (2005). Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 124, 740-748.
25. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, et al. (2005). Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci 20, 977-984.
26. Liszka L, Zielinska-Pajak E, Pajak J, Golka D, and Huszno J (2007). Coexistence of gastrointestinal stromal tumors with other neoplasms. J Gastroenterol 42, 641-649.
27. Orosz Z, Tornoczky T, and Sapi Z (2005). Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Oncol Res 11, 11-21.
28. Rubin BP, Heinrich MC, and Corless CL (2007). Gastrointestinal stromal tumour. Lancet 369, 1731-1741.
29. Agaimy A, Wunsch PH, Sobin LH, Lasota J, and Miettinen M (2006). Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 23, 120-129.
30. Au WY, Ho KM, and Shek TW (2004). Papillary renal cell carcinoma and gastrointestinal stromal tumor: a unique association. Ann Oncol 15, 843-844.
31. Boni L, Benevento A, Dionigi G, Rovera F, and Dionigi R (2005). Surgical resection for gastrointestinal stromal tumors (GIST): experience on 25 patients. World J Surg Oncol 3, 78.
32. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, and Brennan MF (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231, 51-58.
33. Hassan I, You YN, Dozois EJ, Shayyan R, Smyrk TC, Okuno SH, and Donohue JH (2006). Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 49, 609-615.
34. Maiorana A, Fante R, Maria Cesinaro A, and Adriana Fano R (2000). Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med 124, 682-686.
35. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, and Lasota J (2003). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 27, 625-641.
36. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, and Kindblom LG (2005). Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103, 821-829.
37. Ruka W, Rutkowski P, Nowecki Z, Nasierowska-Guttmejer A, and Debiec-Rychter M (2004). Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monit 10, LE13-LE14.
38. Tornoczky T and Kover E (2005). Multiple soft tissue sarcomas. Cancer 104, 440-441; author reply 441.
39. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, and Krasnodebski IW (2006). Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol 12, 5360-5362.
40. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, and Demetri G (2002). Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3, 655-664.
41. Tran T, Davila JA, and El-Serag HB (2005). The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100, 162-168.
42. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, and Becker H (2003). Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90, 332-339.
43. Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, and Koniaris LG (2007). Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 11, 114-125.
44. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, and Ott MJ (2001). The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136, 383-389.
45. Rubio J, Marcos-Gragera R, Ortiz MR, Miro J, Vilardell L, Girones J, Hernandez-Yague X, Codina-Cazador A, Bernado L, Izquierdo A, et al. (2007). Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. Eur J Cancer 43, 144-148.
46. Miettinen M, Sobin LH, and Lasota J (2005). Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29, 52-68.
47. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, and Tsuneyoshi M (2005). Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36, 828-837.
48. Cameron RI, Maxwell P, Jenkins D, and McCluggage WG (2002). Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 41, 313-321.
49. O'Neill CJ and McCluggage WG (2006). p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 13, 8-15.
50. Munot K, Bell SM, Lane S, Horgan K, Hanby AM, and Speirs V (2006). Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol 37, 989-999.
51. Hornick JL and Fletcher CDM (2007). The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38, 679-687.
52. Miettinen M and Lasota J (2006). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23, 70-83.